An investigative migraine prophylaxis medication reduces the amount of time people experience migraine headache in as little as three days, according to new research.
Published online June 8 in the American Academy of Neurology’s journal Neurology, the research showed that the initial effects of the drug, TEV-48125 (Teva), were seen between three and seven days.
“Most people who receive preventive medication for chronic migraine stop using them, and one reason for that is the drugs